Tag Archives: MNK

Hot Value Stocks To Own Right Now

Northern Trust Corp grew its stake in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 16.9% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 543,774 shares of the biopharmaceutical company’s stock after buying an additional 78,445 shares during the period. Northern Trust Corp owned 1.10% of Arena Pharmaceuticals worth $21,479,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. California Public Employees Retirement System lifted its position in shares of Arena Pharmaceuticals by 3.4% during the 4th quarter. California Public Employees Retirement System now owns 51,400 shares of the biopharmaceutical company’s stock valued at $1,746,000 after buying an additional 1,700 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Arena Pharmaceuticals by 5.0% during the 1st quarter. Rhumbline Advisers now owns 37,698 shares of the biopharmaceutical company’s stock valued at $1,489,000 after buying an additional 1,810 shares in the last quarter. Swiss National Bank lifted its position in shares of Arena Pharmaceuticals by 4.9% during the 4th quarter. Swiss National Bank now owns 66,730 shares of the biopharmaceutical company’s stock valued at $2,267,000 after buying an additional 3,100 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Arena Pharmaceuticals by 23.0% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 20,043 shares of the biopharmaceutical company’s stock valued at $792,000 after buying an additional 3,743 shares in the last quarter. Finally, American International Group Inc. lifted its holdings in Arena Pharmaceuticals by 15.8% in the 1st quarter. American International Group Inc. now owns 30,671 shares of the biopharmaceutical company’s stock worth $1,212,000 after purchasing an additional 4,184 shares in the last quarter. 78.23% of the stock is currently owned by hedge funds and other institutional investors.

Hot Value Stocks To Own Right Now: UGI Corporation(UGI)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Mountain Pacific Investment Advisers Inc. ID reduced its holdings in UGI Co. (NYSE:UGI) by 0.9% during the 1st quarter, HoldingsChannel reports. The fund owned 313,995 shares of the utilities provider’s stock after selling 2,800 shares during the quarter. Mountain Pacific Investment Advisers Inc. ID’s holdings in UGI were worth $13,948,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Quantitative Systematic Strategies LLC boosted its holdings in shares of UGI Co. (NYSE:UGI) by 35.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,986 shares of the utilities provider’s stock after acquiring an additional 2,359 shares during the quarter. Quantitative Systematic Strategies LLC’s holdings in UGI were worth $399,000 at the end of the most recent quarter.

  • [By Logan Wallace]

    Rhumbline Advisers trimmed its stake in shares of UGI Co. (NYSE:UGI) by 2.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 299,796 shares of the utilities provider’s stock after selling 7,970 shares during the quarter. Rhumbline Advisers owned about 0.17% of UGI worth $13,317,000 as of its most recent filing with the Securities and Exchange Commission.

Hot Value Stocks To Own Right Now: HNI Corporation(HNI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Halliburton Company (NYSE: HAL) to report quarterly earnings at $0.42 per share on revenue of $5.75 billion before the opening bell. Halliburton shares fell 0.06 percent to $51.93 in after-hours trading.
    Analysts expect Alphabet Inc. (NASDAQ: GOOGL) to post quarterly earnings at $9.33 per share on revenue of $30.31 billion after the closing bell. Alphabet shares gained 0.24 percent to $1,079.88 in after-hours trading.
    Before the markets open, Lennox International Inc. (NYSE: LII) is projected to report quarterly earnings at $1.09 per share on revenue of $815.16 million. Lennox shares dropped 2.84 percent to close at $197.08 on Friday.
    HNI Corporation (NYSE: HNI) reported retirement of its CEO Stan A. Askren and appointment of Jeffrey D. Lorenger as new CEO. HNI also reported strong earnings for its first quarter. HNI shares fell 3.17 percent to $34.20 in the after-hours trading session.
    Analysts are expecting Hasbro, Inc. (NASDAQ: HAS) to have earned $0.35 per share on revenue of $822.15 million in the latest quarter. Hasbro will release earnings before the markets open. Hasbro shares fell 0.39 percent to $82.49 in after-hours trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

Hot Value Stocks To Own Right Now: Orange(ORAN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Orange (ORAN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Anders Bylund, Timothy Green, and Dan Caplinger]

    The trick is to separate high-quality income generators from their lower-quality peers. So we asked a few of your fellow investors here at The Motley Fool to share their best dividend ideas with yields of 4% or more. Read on to see why they recommend tech titanInternational Business Machines(NYSE:IBM), international telecomOrange(NYSE:ORAN), and energy giantExxonMobil(NYSE:XOM).

  • [By Shane Hupp]

    ValuEngine downgraded shares of Orange (NYSE:ORAN) from a buy rating to a hold rating in a research report released on Monday morning.

    ORAN has been the topic of several other reports. Zacks Investment Research cut Orange from a hold rating to a sell rating in a research report on Wednesday, April 25th. BNP Paribas raised Orange from an underperform rating to a neutral rating in a research report on Tuesday, January 23rd. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Orange has a consensus rating of Hold and an average price target of $19.00.

Hot Value Stocks To Own Right Now: Mallinckrodt plc(MNK)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Stifel Financial Corp grew its position in Mallinckrodt PLC (NYSE:MNK) by 154.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,693 shares of the company’s stock after acquiring an additional 31,966 shares during the quarter. Stifel Financial Corp’s holdings in Mallinckrodt were worth $751,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Dean Foods Company (NYSE: DF) is projected to report quarterly earnings at $0.11 per share on revenue of $1.85 billion.
    Discovery, Inc. (NASDAQ: DISCA) is expected to report quarterly earnings at $0.44 per share on revenue of $1.99 billion.
    Jacobs Engineering Group Inc. (NYSE: JEC) is estimated to report quarterly earnings at $0.89 per share on revenue of $3.63 billion.
    Henry Schein, Inc. (NASDAQ: HSIC) is expected to report quarterly earnings at $0.92 per share on revenue of $3.17 billion.
    Gartner, Inc. (NYSE: IT) is projected to report quarterly earnings at $0.57 per share on revenue of $926.18 million.
    The AES Corporation (NYSE: AES) is estimated to report quarterly earnings at $0.24 per share on revenue of $2.98 billion.
    Expeditors International of Washington, Inc. (NASDAQ: EXPD) is projected to report quarterly earnings at $0.64 per share on revenue of $1.71 billion.
    US Foods Holding Corp. (NYSE: USFD) is expected to report quarterly earnings at $0.32 per share on revenue of $5.98 billion.
    DISH Network Corporation (NASDAQ: DISH) is expected to report quarterly earnings at $0.7 per share on revenue of $3.50 billion.
    Zebra Technologies Corporation (NASDAQ: ZBRA) is estimated to report quarterly earnings at $2.06 per share on revenue of $936.98 million.
    Camping World Holdings, Inc. (NYSE: CWH) is expected to report quarterly earnings at $0.42 per share on revenue of $1.06 billion.
    Perrigo Company plc (NYSE: PRGO) is projected to report quarterly earnings at $1.14 per share on revenue of $1.21 billion.
    Petróleo Brasileiro S.A. – Petrobras (NYSE: PBR) is estimated to report quarterly earnings at $0.28 per share on revenue of $23.80 billion.
    JD.com, Inc. (NYSE: JD) is projected to report quarterly earnings at $0.18 per share on revenue of $15.65 billion.
    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) is projected to report quarterly earnings at $0.6 per share o
  • [By Max Byerly]

    Mallinckrodt (NYSE: MNK) and ANI Pharmaceuticals Inc Common Stock (NASDAQ:ANIP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

  • [By Joseph Griffin]

    Mallinckrodt PLC (NYSE:MNK) shares rose 2.8% during trading on Thursday . The company traded as high as $18.64 and last traded at $18.71. Approximately 129,799 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 2,879,913 shares. The stock had previously closed at $18.20.

Hot Value Stocks To Own Right Now: Hudson Technologies, Inc.(HDSN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    MDC Partners Inc. (NASDAQ: MDCA) fell 23.4 percent to $5.25 in pre-market trading after a first-quarter earnings miss.
    Hudson Technologies Inc. (NASDAQ: HDSN) shares fell 15.1 percent to $3.48 in pre-market trading after the company reported downbeat Q1 earnings.
    Nuance Communications, Inc. (NASDAQ: NUAN) fell 14 percent to $13.15 in pre-market trading after the company posted downbeat Q2 earnings and lowered FY18 organic growth guidance.
    Myomo, Inc. (NYSE: MYO) fell 13.2 percent to $3.10 in pre-market trading after reporting downbeat quarterly results.
    Rowan Companies plc (NYSE: RDC) shares fell 10.7 percent to $14.13 in pre-market trading after climbing 8.50 percent on Wednesday.
    BT Group plc (NYSE: BT) fell 9 percent to $14.80 in pre-market trading after the company reported Q4 results and announced plans to cut 13,000 jobs over the next three years.
    Exelixis, Inc. (NASDAQ: EXEL) fell 8.3 percent to $19.90 in pre-market trading after the company disclosed that IMblaze370 Phase 3 pivotal trial of atezolizumab and cobimetinib in patients with heavily pretreated locally advanced or metastatic colorectal cancer did not meet primary endpoint.
    Infinera Corporation (NASDAQ: INFN) fell 8.2 percent to $10.80 in pre-market trading after reporting Q1 results.
    Synaptics, Incorporated (NASDAQ: SYNA) shares fell 7.4 percent to $43.00 in pre-market trading. Synaptics reported better-than-expected earnings for its third quarter, while sales missed estimates.
    Randgold Resources Limited (NASDAQ: GOLD) shares fell 7.4 percent to $76.23 in pre-market trading after reporting Q1 earnings.
    Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares fell 7 percent to $59.36 in pre-market trading. Integra LifeSciences priced its 5.25 million share public offering of common stock at $58.50 per share.
    Array BioPharma Inc. (NASDAQ: ARRY) shares fell 6.9 percent to $12.75 in pre-m

  • [By Lisa Levin]

    Hudson Technologies Inc. (NASDAQ: HDSN) was down, falling around 29 percent to $2.9199 after the company reported downbeat Q1 earnings.

    Commodities

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Hudson Technologies (HDSN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin] Gainers
    Comstock Holding Companies, Inc. (NASDAQ: CHCI) shares surged 115.8 percent to $4.3591. Comstock reported conversion of the majority of its unsecured, short-term debt into non-convertible preferred equity.
    Stellar Biotechnologies, Inc. (NASDAQ: SBOT) jumped 38.2 percent to $3.0251 after the company disclosed that it achieved robust viral clearance for its manufacturing process.
    Universal Corporation (NYSE: UVV) surged 26.7 percent to $61.40 after reporting fiscal Q4 results.
    Hudson Technologies Inc. (NASDAQ: HDSN) rose 18.9 percent to $2.58.
    Evolus, Inc. (NASDAQ: EOLS) shares gained 17.8 percent to $22.8009.
    The Cato Corporation (NYSE: CATO) shares gained 17.5 percent to $21.07 after the company posted better-than-expected first-quarter results.
    Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.9 percent to $3.3613.
    Destination Maternity Corporation (NASDAQ: DEST) shares gained 15.5 percent to $3.35 after the board announced late Wednesday the election of four activist-backed director nominees. Three women and one man comprise the selected group championed by NGM Capital’s Nathan Miller and Kenosis Capital’s Peter O’Malley. Destination Maternity had advocated for another slate of three men and interim CEO Melissa Payner-Gregor. The new directors are Holly Alden, Marla Ryan, Anne-Charlotte Windal and Christopher Morgan.
    AXT, Inc. (NASDAQ: AXTI) rose 15 percent to $7.65.
    nLIGHT, Inc. (NASDAQ: LASR) gained 14.5 percent to $34.27 following Q1 results.
    Achieve Life Sciences, Inc. (NASDAQ: ACHV) rose 14.3 percent to $11.4303.
    Bilibili Inc.. (NASDAQ: BILI) shares climbed 13.9 percent to $14.16 after announcing Q1 results.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) gained 13.2 percent to $2.91 after an amended 13D filing from Steel Partners Holdings shows a raised stake in the company from 6.99 million shares to 29.98 million shares, or a 17.8 percent stake.
    HUYA Inc. (NYSE: HUYA) gained 13.1
  • [By Lisa Levin]

    Hudson Technologies Inc. (NASDAQ: HDSN) was down, falling around 25 percent to $3.07 after the company reported downbeat Q1 earnings.

    Commodities

  • [By Shane Hupp]

    Hudson Technologies (NASDAQ:HDSN) released its quarterly earnings results on Wednesday. The industrial products company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.01 by ($0.03), Bloomberg Earnings reports. Hudson Technologies had a return on equity of 6.44% and a net margin of 1.64%. The business had revenue of $42.43 million during the quarter, compared to the consensus estimate of $45.88 million.

stock market performance

If I have to vote for one of the strangest market reactions to a quarterly report, GoPro’s (GPRO) recent Q3’17 numbers are probably on the top of my list.

First of all, GPRO’s management had guided higher two months earlier, stating revenue will be in the upper range between $290M and $310M. Not only did it beat that number (which was already something the market did not expect), but it beat it by a whopping $20M and the revenue increase was 37% Y/Y.

If that was not enough, the company reported GAAP EPS of $0.10 and adjusted EPS of $0.15, blowing the consensus by $0.13.

And the end result was that the stock was down by about 11% on the reporting date. Supposedly, the reason for the drop was guidance that called for about $470M in revenue for Q4 vs. the $520M the market was expecting.

So is the market right or wrong? The market is dead wrong, of course, it just doesn’t know it yet. To give you just one reason why the market is wrong, please take a look at the chart below:

stock market performance: Mallinckrodt plc(MNK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after Citron Research accused the company of fraud.

    Getty Images

    Mallinckrodt tumbled 12% to $59.60 today, while the S&P 500 declined 0.2% to 2,176.94.

    Leerink’s Jason Gerberry and Etzer Darout explain the allegations:

    Mallinckrodtshares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net., although it’s unclear to what extent Acthar CMS sales are overstated.

    The report suggestsMallinckrodt mgmt understated combined Medicaid/Medicare sales on an investor call, saying it was about a little bit higher than a quarter of the business vs. gross sales on CMS dashboard implying sales were 61% of total Acthar net revenue (an apples to oranges comparison). We dont know the exact net sales of Acthar to Medicare/Medicaid, but we believe it is safe to assume Medicaid, after CPI price penalties had high discounts/rebates and assuming an 80% gross-to-net ratio on the Medicare book ($504m gross) suggests Acthar net sales would be closer to 38-45% range vs. the 61% figure cited in the short-report. Why this may matter Acthar Gel is an old product lacking good randomized, controlled data consistent with most products approved in the modern era. The report appears to be an attempt to call into question whether the government should be paying Acthars average $80-100k net price/patient/year by calling to this to the attention of government figures who have been targeting excessive drug pricing issues. This type of issue became a major headache for Mylan (MYL) investors recently with EpiPen.Mallinckrodt is presenting at a compe

  • [By Keith Speights]

    That’s the question investors are trying to answer about how President Trump’s policies might impact healthcare stocks. So far, specific policy proposals put forward by the president appear likely to cause significant problems for certain healthcare stocks. Here’s why three of President Trump’s policies could be downright terrible for Molina Healthcare(NYSE:MOH), Mallinckrodt (NYSE:MNK), and Illumina (NASDAQ:ILMN).

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after its earnings topped the Street consensus but offered commentary that spooked investors.

    Agence France-Presse/Getty Images

    Shares of Mallinckrodt dropped 9.1% to $52.42, while the S&P 500 rose 0.1%.

    Barclays analyst Douglas Tsao and Morgan Williams callMallinckrodt’s plunge “outsized.” They explain why:

    In our view the sell-off afterMallinckrodt reported CY3Q16 earnings is outsized considering much of the disclosure on the call was largely expected, including specialty generics weakness and the 2017 outlook, which seemed relatively mild. While outsized Acthar contribution to EBITDA may be accounting for some of the sell-off, wed argue that there is benefit to the brand outperforming, especially considering the need to offset Therakos production issues in CY4Q16 and CY1Q17 as well as specialty generics weakness. We recognize some lingering headline risk associated with media reports criticizing the cost of Acthar to Medicare, after CMS released its prescription drug spending dashboard.

    Mallinckrodt’s market capitalization fell to $5.7 billion today from $6.2 billion yesterday. It reported net income of $306 million on revenue of $3.3 billion in 2015.

    This marks the third time in less than two weeks that Mallinckrodt was the S&P 500′s biggest loser.

  • [By Johanna Bennett]

    Sell-side analysts continue to defend drug maker Mallinckrodts (MNK) shares on the heel of Citron Researchs report on the company released last week.

    Earlier today, UBS analyst Marc Goodman and his team weighed into the fray, proclaiming that a misunderstood situation creates opportunity.

    Goodman, who rates Mallinckrodt at a buy with a $92 price target, argues that Mallinckrodt is a different breed from other specialty drug makers, with high-quality earnings, sales growth fueled by volume not price hikes and an emerging pipeline we think is not just underappreciated but really not even part of the conversation with most investors.

    Also, he argues that Mallinckrodt continues to be misunderstood by investors.

    Goodman goes into goes into more detail:

    we were surprised this past week by the debate around Acthar’s Medicare exposure (~30% or ~40%), which in our view has little relevance to the overall MNK story. The key debate since the Questcor deal has been Acthar payer coverage and concerns for more barriers andor coverage blocks by the payers. There was reason for concern just 2 years ago, in our view, as several important payers increased barriers. But mgt’s aggressive focus on enhancing clinical and health-economics data to help support better coverage seems to be working and has resulted in improved coverage, which we believe is still not well appreciated.

    Mallinckrodt shares continue to climb today, rising 4.8% to a recent $57.20.

stock market performance: WashingtonFirst Bankshares Inc(WFBI)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of CASTLE CREEK CAPITAL PARTNERS IV, LP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=CASTLE+CREEK+CAPITAL+PARTNERS+IV%2C+LP

    These are the top 5 holdings of CASTLE CREEK CAPITAL PARTNERS IV, LPGuaranty Bancorp (GBNK) – 1,448,849 shares, 39.1% of the total portfolio. MBT Financial Corp (MBTF) – 1,876,423 shares, 23.6% of the total portfolio. WashingtonFirst Bankshares Inc (WFBI) – 489,377 shares, 15.19% of the total portfolio. Shares added by 4558.07%Eastern Virginia Bankshares Inc (EVBS) – 1,061,225 shares, 12.33% of the total portfolio. First NBC Bank Holding Co (FNBC) – 2,205,382 shares, 9.78% of the total portfolio. Added: Wa

stock market performance: Monotype Imaging Holdings Inc.(TYPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Monotype Imaging Holdings Inc. (NASDAQ: TYPE) were down around 12 percent to $20.90 after the company posted downbeat quarterly earnings.

  • [By Lisa Levin]

    Wednesday afternoon, the non-cyclical consumer goods & services shares surged 0.61 percent. Meanwhile, top gainers in the sector included Monotype Imaging Holdings Inc. (NASDAQ: TYPE), up 9 percent, and Semiconductor Manufacturing Int'l (ADR) (NYSE: SMI), up 6 percent.

stock market performance: CGG(CGG)

Advisors’ Opinion:

  • [By Jonas Elmerraji]

    First up is French oil service firm CGG Veritas (CGG)
    . The Eurozone-based energy stock hasn’t exactly posted blockbuster performance in 2013, but investors who ignore CGG for the final stretch of the year could be making a big mistake. That’s because of a bullish technical pattern that’s emerging in shares right now.

    CGG spent most of the last eight months looking anything but bullish. But an ascending triangle pattern is changing that. The pattern is formed by horizontal resistance to the upside at $26, and uptrending support to the below shares. Basically, as CGG bounces in between those two technical levels, it’s getting squeezed closer and closer to a breakout above $26. When that happens, traders have a buy signal.

    The ascending triangle pattern in CGG Veritas isn’t exactly textbook. That’s because the setup is forming at the bottom of a downtrend, rather than in the middle of an uptrend – but it’s a mistake to get caught up on the textbook pictures of what trading patterns are supposed to look like. On a move through $26, the trading implications are just as actionable.

  • [By Lisa Levin]

    CGG SA (ADR) (NYSE: CGG) shares shot up 32 percent to $7.15 after the company reported an agreement in principle on financial restructuring plan with main creditors and DNCA.

  • [By Lisa Levin]

    Friday afternoon, the energy sector proved to be a source of strength for the market. Leading the sector was strength from CGG SA (ADR) (NYSE: CGG) and Geospace Technologies Corporation (NASDAQ: GEOS).

stock market performance: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston

good stocks to purchase

Microsoft is vowing to defend its Dreamer employees in court if the government tries to deport them.

Brad Smith, the company president, said in a blog post Tuesday that President Trump’s decision to end the program known as DACA is “a big step back for our entire country.” The company said it knows of 39 employees covered by the protection.

“If the government seeks to deport any one of them, we will provide and pay for their legal counsel,” he wrote.

Smith said the company will also explore whether it can intervene directly in any such case.

“In short, if Dreamers who are our employees are in court, we will be by their side,” Smith said.

DACA allows undocumented immigrants who were brought to the United States as children to live, work and study in the country without fear of deportation. Attorney General Jeff Sessions gave Congress six months to act before anyone loses the ability to live in the United States.

Microsoft’s (MSFT, Tech30) Smith said Congress should pass legislation that protects DACA, even before it tackles tax reform.

good stocks to purchase: Tetra Technologies, Inc.(TTI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Energy sector was the top gainer in the US market on Wednesday. Top gainers in the sector included TETRA Technologies, Inc. (NYSE: TTI), CARBO Ceramics Inc. (NYSE: CRR), and Atwood Oceanics, Inc. (NYSE: ATW).

  • [By Lisa Levin]

    Wednesday afternoon, the energy sector proved to be a source of strength for the market. Leading the sector was strength from TETRA Technologies, Inc. (NYSE: TTI) and Abraxas Petroleum Corp. (NASDAQ: AXAS).

good stocks to purchase: CyberArk Software Ltd.(CYBR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Citigroup Inc (NYSE: C) to report quarterly earnings at $1.26 per share on revenue of $17.71 billion before the opening bell. Citigroup shares rose 0.30 percent to $67.22 in after-hours trading.
    Analysts are expecting JPMorgan Chase & Co. (NYSE: JPM) to have earned $1.65 per share on revenue of $25.61 billion in the latest quarter. JPMorgan will release earnings before the markets open. JPMorgan shares gained 0.48 percent to $93.55 in after-hours trading.
    Cyberark Software Ltd (NASDAQ: CYBR) lowered its guidance for the second quarter. The company now expects total revenue of $57.0 million to $57.5 million, versus earlier guidance of $61.0 million to $62.0 million. Cyberark shares dipped 17.65 percent to $42.00 in the after-hours trading session.
    Before the opening bell, First Republic Bank (NYSE: FRC) is projected to report quarterly earnings at $1.1 per share on revenue of $675.70 million. First Republic Bank shares dropped 0.80 percent to close at $101.35 on Thursday.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Joe Tenebruso]

    CyberArk Software (NASDAQ:CYBR) reported fourth-quarter financial results on Feb. 9. The Israeli cybersecurity specialist continues to win new business for its “privileged account” security solutions, which help to protect against cyberattacks that use insider privileges to penetrate network perimeters and assault the most sensitive areas of an enterprise’s IT infrastructure.

good stocks to purchase: Carnival Corporation(CCL)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    How about individual stories? Tuesday I was pleasantly surprised by the commentary on both the Darden (DRI) and Carnival (CCL) calls. Weekend dining and lunch were very strong for Darden, parent of Olive Garden, even though CEO Gene Lee acknowledged that it’s competing against “new necessities today, whether smartphones, whether it’s your cable bill, your Netflix bill. I mean, they have increased significantly over the years.” Hmm, is there any wonder why takeout pizza is so strong? Makes me want to buy both Darden and Domino’s (DPZ) .

  • [By Diane Alter]

    At $28.66, SNE shares were up 0.28% in morning trading.

    CES Companies to Watch, No. 3: Carnival (NYSE: CCL)

    Carnival Cruise Line (NYSE: CCL) announced Wednesday at CES 2017 that it will give passengers on board its ships high-tech wearable wristbands – which can also be worn as a pendant or necklace. The device can be used to unlock their room, purchase food, and to pay toplay games such as blackjack.

  • [By WWW.THESTREET.COM]

    That’s not to say the consumer never leaves the house, but when they do, they shop for their homes at Home Depot (HD) and Home Goods, the TJX Stores (TJX) chain that’s knocking it out of the park. The consumer is also visiting theme parks like Six Flags (SIX) and Walt Disney (DIS) and they’re also going on Carnival Cruises (CCL) .

  • [By Rick Munarriz]

    Carnival Corporation & plc (NYSE:CCL) (NYSE:CUK)shareholders have to be feeling pretty good these days. The stock hit yet another new high on Friday, and the stock is trading 13% higher so far in 2017.It’s been smooth sailing so far this year, but the first big test comes on Tuesday morning when the world’s largest cruise line operator reports financial results for its fiscal first quarter.

good stocks to purchase: New York Community Bancorp, Inc.(NYCB)

Advisors’ Opinion:

  • [By Paul Ausick]

    New York Community Bank Inc. (NYSE: NYCB) dropped 5% Wednesday to post a new low of $13.05 after closing at $13.74 Tuesday night. The stock’s 52-week high is $17.68. Volume was about 80% above the daily average of around 4.8 million shares. The bank reported disappointing results this morning.

good stocks to purchase: Occidental Petroleum Corporation(OXY)

Advisors’ Opinion:

  • [By Chris Lange]

    Occidental Petroleum Corp.s (NYSE: OXY) short interest increased to 16.11 million shares from the previous reading of 15.70 million. Shares were recently at $62.83, in a 52-week range of $61.01 to $78.48.

  • [By Ben Levisohn]

    We have seen several dividend cuts in the recent past, including Anadarko Petroleum cutting its dividend by 81%…and we expect more companies to follow suit. Chesapeake Energy (CHK), ConocoPhillips (COP), Encana,Marathon Oil and Noble Energy (NBL) are among energy companies that have also cut dividends in the past 12 months, but dividend requirements even after several cuts will consume ~26% of 2016 estimated cash flow at current dividend rates (15% excluding Occidental Petroleum (OXY)) for the large cap E&Ps we cover. We believe most of the companies with a dividend yield of more than 1.5% should consider cutting the dividend and find the following companies more likely than not to reduce dividends:Apache (2.5% yield),Devon Energy (4%),Encana (1.5%) andMarathon Oil (2.5%). We believe Canadian Natural Resource (CNQ) (3.0%) is likely to maintain its dividend while Occidental (4.5%) has the financial strength to maintain or even increase the dividend…

  • [By Chris Lange]

    Occidental Petroleum Corp.s (NYSE: OXY) short interest increased to 17.60 million shares from the previous reading of 15.53 million. Shares closed most recently at $66.90, in a 52-week range of $58.24 to $78.48.

  • [By Paul Ausick]

    Occidental Petroleum Corp. (NYSE: OXY) dropped about 1.6% Friday, to post a new 52-week low of $64.19 after closing at $65.25 on Thursday. The stock’s 52-week high is $78.48. Volume was about 15% below the daily average of around 4.7 million shares. The company had no specific news.

  • [By Michael Flannelly]

    Early on Monday, analysts at Deutsche Bank lowered their price target on Occidental Petroleum Corporation (OXY) to reflect a lower-than-expected valuation of an asset that the oil and gas exploration company is trying to sell.

    Though the analysts lowered OXY’s price target from $114 to $109, they still maintain a “Buy” rating on the stock. The new price target suggests a 22% upside to the stock’s Friday closing price of $89.49.

    Deutsche Bank analyst Paul Sankey said, “Bloomberg Finance LP reports that Oxy is seeking sale of 40% of Mideast operations for around $8bn, which would imply $20bn total value for the unit. However reportedly some suitors are valuing the asset at around $15bn. This is a relatively negative valuation against our previous view that Oxy would be seeking $25+bn for its MENA business. We are cutting our price target to $109/share to reflect this lower implied valuation.”

    Occidental Petroleum shares were up 96 cents, or 1.07%, during pre-market trading on Monday. The stock is up 16.81% year-to-date.

good stocks to purchase: Mallinckrodt plc(MNK)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today as weakness that began last month even before its fourth-quarter earnings continued into year end.

    Agence France-Presse/Getty Images

    Mallinckrodtdropped 2.7% to $51.77 today, while the S&P 500 rose 0.2% to 2,268.88.

    Mallinckrodt was the biggest loser in the S&P 500 for two consecutive days in mid-November, and again after reporting its earnings.

    Mallinckrodt’s market capitalization fell to $5.5 billion today from $5.6 billion yesterday. It reported net income of $489 million on sales of $3.38 billion in fiscal 2016.

    Mallinckrodt has dropped 31% so far this year.

  • [By Johanna Bennett]

    Sell-side analysts continue to defend drug maker Mallinckrodts (MNK) shares on the heel of Citron Researchs report on the company released last week.

    Earlier today, UBS analyst Marc Goodman and his team weighed into the fray, proclaiming that a misunderstood situation creates opportunity.

    Goodman, who rates Mallinckrodt at a buy with a $92 price target, argues that Mallinckrodt is a different breed from other specialty drug makers, with high-quality earnings, sales growth fueled by volume not price hikes and an emerging pipeline we think is not just underappreciated but really not even part of the conversation with most investors.

    Also, he argues that Mallinckrodt continues to be misunderstood by investors.

    Goodman goes into goes into more detail:

    we were surprised this past week by the debate around Acthar’s Medicare exposure (~30% or ~40%), which in our view has little relevance to the overall MNK story. The key debate since the Questcor deal has been Acthar payer coverage and concerns for more barriers andor coverage blocks by the payers. There was reason for concern just 2 years ago, in our view, as several important payers increased barriers. But mgt’s aggressive focus on enhancing clinical and health-economics data to help support better coverage seems to be working and has resulted in improved coverage, which we believe is still not well appreciated.

    Mallinckrodt shares continue to climb today, rising 4.8% to a recent $57.20.

  • [By Paul Ausick]

    Mallinckrodt plc (NYSE: MNK) dropped 39% Tuesday to post a new 52-week low of $19.01 after closing at $31.18 on Monday. The 52-week high is $68.12. Volume was around 32 million, about 16 times the daily average of about 2 million. The generic drug maker missed analysts revenue estimate.

  • [By Keith Speights]

    Although 2016 wasn’t exactly the greatest year for healthcare stocks in general, there really aren’t very many true bargains to be found in the industry. However, three healthcare stocks do appear to be priced well below what they’re worth. Here’s why Gilead Sciences (NASDAQ:GILD), Lantheus Holdings (NASDAQ:LNTH), and Mallinckrodt (NYSE:MNK) look to be ridiculously cheap right now.

  • [By Ben Levisohn]

    Mallinckrodt (MNK) tumbled to the bottom of the S&P 500 today after Citron Research accused the company of fraud.

    Getty Images

    Mallinckrodt tumbled 12% to $59.60 today, while the S&P 500 declined 0.2% to 2,176.94.

    Leerink’s Jason Gerberry and Etzer Darout explain the allegations:

    Mallinckrodtshares are down -7-8% based on a short report citing CMS dashboard data which call into question Acthar Gel sales derived from government sources (CMS; Medicaid & Medicare). The report appears to overstate Acthar CMS sales as a percent of total product sales, as the methodology utilized by CMS drug spending dashboard for Medicare spend is based on gross sales, not net., although it’s unclear to what extent Acthar CMS sales are overstated.

    The report suggestsMallinckrodt mgmt understated combined Medicaid/Medicare sales on an investor call, saying it was about a little bit higher than a quarter of the business vs. gross sales on CMS dashboard implying sales were 61% of total Acthar net revenue (an apples to oranges comparison). We dont know the exact net sales of Acthar to Medicare/Medicaid, but we believe it is safe to assume Medicaid, after CPI price penalties had high discounts/rebates and assuming an 80% gross-to-net ratio on the Medicare book ($504m gross) suggests Acthar net sales would be closer to 38-45% range vs. the 61% figure cited in the short-report. Why this may matter Acthar Gel is an old product lacking good randomized, controlled data consistent with most products approved in the modern era. The report appears to be an attempt to call into question whether the government should be paying Acthars average $80-100k net price/patient/year by calling to this to the attention of government figures who have been targeting excessive drug pricing issues. This type of issue became a major headache for Mylan (MYL) investors recently with EpiPen.Mallinckrodt is presenting at a compe